Caribou Biosciences will soon start testing its new CAR T-cell therapy candidate, CB-011, in people with relapsed or refractory multiple myeloma. A Phase 1 trial will begin enrolling eligible adults in early 2023 at multiple centers, according to the company. The announcement follows clearance of the company’s investigational…
The first patient has been dosed in Ichnos Sciences’ Phase 1/2 clinical trial investigating ISB 1442, an experimental bi-specific antibody treatment for people with relapsed or refractory multiple myeloma. ISB 1442 targets two proteins on cancer cells, CD47 and CD38, and also binds to immune cells. These simultaneous…
Talquetamab, a first-in-class antibody treatment being developed by Janssen Research & Development, has been granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) for hard-to-treat multiple myeloma. The designation was awarded based on the positive safety and efficacy findings of a Phase 1/2 clinical trial involving adults…
SteroTherapeutics has entered into an exclusive license agreement with Moffitt Cancer Center and Florida Atlantic University Research Corporation to develop matrix metalloproteinase 13 (MMP-13) inhibitors for treating multiple myeloma. “This partnership with Moffitt Cancer Center and the Research Institute of Florida Atlantic University will allow us to…
Get regular updates to your inbox.